ALX ONCOLOGY HOLDINGS INC Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $6.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $15.91M, a 422.19% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $3.05M.
- ALX ONCOLOGY HOLDINGS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$8.37M, a 158.20% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $14.37M.
- ALX ONCOLOGY HOLDINGS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$1.19M.
- ALX ONCOLOGY HOLDINGS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$4.84M.
- ALX ONCOLOGY HOLDINGS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$26.42M.
- ALX ONCOLOGY HOLDINGS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$314.78M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.51M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $15.91M 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | -$1.19M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $5.88M 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $1.74M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $3.05M 10-Q · filed 2026-05-08 | |||
| 2024-12-31 | -$4.84M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | -$6.30M 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | -$6.87M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$8.37M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$26.42M 10-K · filed 2026-03-09 | |||
| 2023-09-30 | -$29.24M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$10.78M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $14.37M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$314.78M 10-K · filed 2025-03-06 | |||
| 2022-09-30 | -$314.55M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$297.22M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$204.51M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$70.55M 10-K · filed 2024-03-07 | |||
| 2021-09-30 | -$49.07M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$24.25M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$4.36M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $425.20M 10-K · filed 2023-03-09 | |||
| 2020-09-30 | $250.47M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $89.09M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $96.02M 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $755.00K 10-K · filed 2022-02-28 | |||
| 2019-09-30 | -$2.36M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $826.00K 10-Q · filed 2020-08-27 | |||
| 2018-12-31 | -$13.84M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |